DAB389IL-2 diphtheria toxin targeted to interleukin-2 receptors on activated T cells data

SRGN presented data from a Phase I/II trial of three doses of its second-generation fusion toxin showing that the low and mid-range doses tested were tolerated and potentially active, although the number of patients was too small to allow statistical analysis.

Seven of the 43 patients who had two courses of the agent had improvement in their arthritic symptoms. Improvement consisted of more than 50 percent reduction in the number of swollen joints and the number of painful joints, as in self-reported pain and morning stiffness. The patients in the study had severe, progressing arthritis for at least 10 years that had resisted standard therapy. ...